Celyad Oncology SA (CLYYF)
USD 0.53
(-22.44%)
USD 0.53
(-22.44%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 33 Thousand EUR | 102.29% |
| 2022 | -1.44 Million EUR | 5.26% |
| 2021 | -1.52 Million EUR | -30500.0% |
| 2020 | 5000.00 EUR | -16.67% |
| 2019 | 6000.00 EUR | -99.81% |
| 2018 | 3.11 Million EUR | 2.98% |
| 2017 | 3.02 Million EUR | -64.29% |
| 2016 | 8.47 Million EUR | 232.78% |
| 2015 | -6.37 Million EUR | -20677.42% |
| 2014 | 31 Thousand EUR | 101.28% |
| 2013 | -2.41 Million EUR | 63.57% |
| 2012 | -6.62 Million EUR | -14.87% |
| 2011 | -5.77 Million EUR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 5000.00 EUR | 0.0% |
| 2023 Q2 | -397 Thousand EUR | 0.0% |
| 2023 Q4 | 33 Thousand EUR | 0.0% |
| 2022 Q4 | -469 Thousand EUR | 0.0% |
| 2022 Q2 | -971 Thousand EUR | 0.0% |
| 2022 Q1 | - EUR | 100.0% |
| 2022 FY | - EUR | 0.0% |
| 2021 Q4 | -679 Thousand EUR | 0.0% |
| 2021 Q2 | -841 Thousand EUR | 0.0% |
| 2021 Q3 | - EUR | 100.0% |
| 2021 Q1 | - EUR | 100.0% |
| 2021 FY | - EUR | -100.0% |
| 2020 Q2 | 5000.00 EUR | 0.0% |
| 2020 FY | 5000.00 EUR | -16.67% |
| 2020 Q4 | -937 Thousand EUR | 0.0% |
| 2020 Q3 | - EUR | -100.0% |
| 2019 FY | 6000.00 EUR | -99.81% |
| 2019 Q1 | 1500.00 EUR | -99.75% |
| 2019 Q2 | -894.5 Thousand EUR | -59733.33% |
| 2019 Q4 | 6000.00 EUR | 0.0% |
| 2018 Q2 | 2.51 Million EUR | 223.34% |
| 2018 FY | 3.11 Million EUR | 2.98% |
| 2018 Q4 | 597 Thousand EUR | 0.0% |
| 2018 Q1 | 778.75 Thousand EUR | 3144.79% |
| 2017 FY | 3.02 Million EUR | -64.29% |
| 2017 Q4 | 24 Thousand EUR | 0.0% |
| 2017 Q2 | 2.97 Million EUR | 293.92% |
| 2017 Q1 | 756.25 Thousand EUR | -91.06% |
| 2016 FY | 8.47 Million EUR | 423400.0% |
| 2016 Q2 | 14 Thousand EUR | -99.34% |
| 2016 Q4 | 8.45 Million EUR | 0.0% |
| 2016 Q1 | 2.11 Million EUR | 105775.0% |
| 2015 Q4 | 2000.00 EUR | 300.0% |
| 2015 FY | 2000.00 EUR | -93.55% |
| 2015 Q3 | 500.00 EUR | 0.0% |
| 2015 Q2 | 500.00 EUR | 0.0% |
| 2015 Q1 | 500.00 EUR | -98.39% |
| 2014 FY | 31 Thousand EUR | 101.28% |
| 2014 Q1 | 7750.00 EUR | 100.25% |
| 2014 Q4 | 31 Thousand EUR | 300.0% |
| 2014 Q2 | 7750.00 EUR | 0.0% |
| 2014 Q3 | 7750.00 EUR | 0.0% |
| 2013 Q1 | -603.8 Thousand EUR | -0.0% |
| 2013 Q2 | -3.19 Million EUR | -428.6% |
| 2013 Q3 | -603.8 Thousand EUR | 81.08% |
| 2013 Q4 | -3.15 Million EUR | -422.55% |
| 2013 FY | -2.41 Million EUR | 63.57% |
| 2012 Q3 | -1.65 Million EUR | -0.0% |
| 2012 Q2 | -1.65 Million EUR | 0.0% |
| 2012 Q1 | -1.65 Million EUR | -0.0% |
| 2012 FY | -6.62 Million EUR | -14.87% |
| 2012 Q4 | -603.8 Thousand EUR | 63.57% |
| 2011 Q1 | -1.44 Million EUR | -0.0% |
| 2011 Q2 | -1.44 Million EUR | 0.0% |
| 2011 Q3 | -1.44 Million EUR | -0.0% |
| 2011 Q4 | -1.65 Million EUR | -14.87% |
| 2011 FY | -5.77 Million EUR | 0.0% |
| 2010 Q4 | -1.44 Million EUR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Capstone Therapeutics Corp. | 9.61 Million USD | 99.657% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | 126.559% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | 99.972% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | 110.328% |
| Qrons Inc. | - USD | -Infinity% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | 168.381% |
| Adynxx, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | -2439.00 USD | 1453.014% |
| BioStem Technologies, Inc. | 15.42 Million USD | 99.786% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 81.309% |
| CSL Limited | 7.56 Billion USD | 100.0% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 100.128% |
| Evofem Biosciences, Inc. | 11.7 Million USD | 99.718% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | 76.512% |
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | 99.78% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | -963.83% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| SQZ Biotechnologies Company | 9.79 Million USD | 99.663% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | 49.793% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | 196.633% |
| Mesoblast Limited | -35.16 Million USD | 100.094% |
| Marizyme, Inc. | 457.7 Thousand USD | 92.79% |
| Genus plc | 178.7 Million USD | 99.982% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| Pharming Group N.V. | 220.1 Million USD | 99.985% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | 46.968% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | 91.954% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | 400.0% |
| ContraFect Corporation | -154 Thousand USD | 121.429% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | 166.0% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | 57.009% |
| IMV Inc. | -962.29 Thousand USD | 103.429% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | 108.516% |
| MultiCell Technologies, Inc. | 49.32 USD | -66809.976% |
| ONE Bio Corp. | 20.12 Million USD | 99.836% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 40.26 Million USD | 99.918% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 48.9 Thousand USD | 32.515% |
| Q BioMed Inc. | -8988.00 USD | 467.156% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | 99.883% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Biomind Labs Inc. | -15.42 Thousand USD | 313.952% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | 99.926% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | 102.891% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | 52.857% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | -4952.00 USD | 766.397% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | 133.841% |
| GB Sciences, Inc. | -624.00 USD | 5388.462% |
| Alpha Cognition Inc. | -86.02 Thousand USD | 138.36% |
| HST Global, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Halberd Corporation | -208.00 USD | 15965.385% |
| Enzolytics Inc. | 30.7 Thousand USD | -7.464% |
| Agentix Corp. | - USD | -Infinity% |
| Resverlogix Corp. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | 93.16% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.1 Billion USD | 99.997% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | 106.414% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | 94.655% |
| Zenith Capital Corp. | - USD | -Infinity% |
| Genscript Biotech Corporation | 409.55 Million USD | 99.992% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | 472.629% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | 139.356% |
| Kadimastem Ltd | -630.13 Thousand USD | 105.237% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | 96.66% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| LadRx Corporation | -11.83 Thousand USD | 378.834% |
| Cell Source, Inc. | - USD | -Infinity% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 81.309% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Affymax, Inc. | 1.35 Million USD | 97.568% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| CytoDyn Inc. | -29 Thousand USD | 213.793% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | 92.667% |
| SYBLEU INC | 11.69 Thousand USD | -182.148% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | 99.284% |
| Bioxytran, Inc. | -8285.00 USD | 498.31% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | - USD | -Infinity% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | 108.847% |
| Neutra Corp. | 14.33 Thousand USD | -130.206% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | 140.244% |
| PureTech Health plc | -1.6 Million USD | 102.059% |
| Coeptis Therapeutics, Inc. | -1 Million USD | 103.296% |
| IXICO plc | 3.27 Million USD | 98.991% |
| IntelGenx Technologies Corp. | -694 Thousand USD | 104.755% |
| Gelesis Holdings, Inc. | -1.79 Million USD | 101.843% |
| CSL Limited | 7.7 Billion USD | 100.0% |
| Cellectis S.A. | 18 Thousand USD | -83.333% |